$664 Million is the total value of Cormorant Asset Management, LP's 84 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 9.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALDR | Buy | ALDER BIOPHARMACEUTICALS INC | $36,673,000 | +46.6% | 1,497,475 | +97.7% | 5.52% | +84.6% |
| HRTX | Buy | HERON THERAPEUTICS INC | $33,233,000 | -26.2% | 1,750,000 | +3.8% | 5.01% | -7.0% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $30,297,000 | +65.0% | 945,000 | +200.0% | 4.56% | +107.7% |
| OMER | OMEROS CORP | $30,066,000 | -2.5% | 1,960,000 | 0.0% | 4.53% | +22.8% | |
| NKTR | Buy | NEKTAR THERAPEUTICS | $27,500,000 | +113.3% | 2,000,000 | +161.4% | 4.14% | +168.7% |
| NVRO | Buy | NEVRO CORP | $27,308,000 | +52.4% | 485,386 | +82.9% | 4.11% | +92.0% |
| ALKS | ALKERMES PLC | $23,933,000 | -56.9% | 700,000 | 0.0% | 3.60% | -45.8% | |
| NBIX | NEUROCRINE BIOSCIENCES INC | $23,884,000 | -30.1% | 603,900 | 0.0% | 3.60% | -12.0% | |
| EGRX | Buy | EAGLE PHARMACEUTICALS INC | $20,250,000 | -42.9% | 500,000 | +25.0% | 3.05% | -28.1% |
| DVAX | Buy | DYNAVAX TECHNOLOGIES CORP | $18,759,000 | +35.0% | 975,000 | +69.6% | 2.83% | +70.0% |
| PTI | New | PROTEOSTASIS THERAPEUTICS IN | $16,644,000 | – | 1,726,599 | +100.0% | 2.51% | – |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $15,379,000 | -33.3% | 245,000 | 0.0% | 2.32% | -16.0% | |
| PTLA | Buy | PORTOLA PHARMACEUTICALS INC | $14,280,000 | -44.5% | 700,000 | +40.0% | 2.15% | -30.1% |
| QTNT | QUOTIENT LTD | $13,368,000 | -45.0% | 1,519,100 | 0.0% | 2.01% | -30.7% | |
| MGNX | Buy | MACROGENICS INC | $13,125,000 | -15.2% | 700,000 | +40.0% | 1.98% | +6.7% |
| CLLS | CELLECTIS S Asponsored ads | $12,901,000 | -11.4% | 469,145 | 0.0% | 1.94% | +11.5% | |
| TSRO | TESARO INC | $12,824,000 | -15.8% | 291,250 | 0.0% | 1.93% | +6.0% | |
| CBPO | CHINA BIOLOGIC PRODS INC | $12,765,000 | -19.6% | 111,500 | 0.0% | 1.92% | +1.2% | |
| ACRS | ACLARIS THERAPEUTICS INC COM | $12,279,000 | -29.7% | 647,944 | 0.0% | 1.85% | -11.4% | |
| CHRS | COHERUS BIOSCIENCES INC | $12,083,000 | -7.5% | 569,130 | 0.0% | 1.82% | +16.4% | |
| ARDX | ARDELYX INC | $11,508,000 | -57.1% | 1,481,075 | 0.0% | 1.73% | -46.0% | |
| VTAE | Buy | VITAE PHARMACEUTICALS INC | $11,503,000 | +1.9% | 1,735,000 | +178.3% | 1.73% | +28.4% |
| SRNE | SORRENTO THERAPEUTICS INC | $11,273,000 | -38.2% | 2,095,334 | 0.0% | 1.70% | -22.2% | |
| NERV | Buy | MINERVA NEUROSCIENCES INC | $10,763,000 | +54.9% | 1,752,946 | +53.1% | 1.62% | +95.1% |
| MRTX | MIRATI THERAPEUTICS INC | $10,601,000 | -32.3% | 495,356 | 0.0% | 1.60% | -14.7% | |
| DXCM | DEXCOM INC | $10,390,000 | -17.1% | 153,000 | 0.0% | 1.56% | +4.4% | |
| CELG | New | CELGENE CORP | $10,009,000 | – | 100,000 | +100.0% | 1.51% | – |
| RMTI | ROCKWELL MEDICAL INC | $8,299,000 | -26.7% | 1,105,000 | 0.0% | 1.25% | -7.7% | |
| NVAX | NOVAVAX INC | $8,256,000 | -38.5% | 1,600,000 | 0.0% | 1.24% | -22.5% | |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $8,168,000 | -34.0% | 450,000 | 0.0% | 1.23% | -16.9% | |
| MYOK | MYOKARDIA INC | $8,069,000 | -26.9% | 753,388 | 0.0% | 1.22% | -7.9% | |
| ADXS | ADVAXIS INC | $7,224,000 | -10.2% | 800,000 | 0.0% | 1.09% | +13.0% | |
| RARE | ULTRAGENYX PHARMACEUTICAL IN | $6,932,000 | -43.6% | 109,500 | 0.0% | 1.04% | -29.0% | |
| CPXX | New | CELATOR PHARMACEUTICALS INC | $6,839,000 | – | 620,000 | +100.0% | 1.03% | – |
| LPCN | LIPOCINE INC NEW | $6,767,000 | -21.5% | 666,666 | 0.0% | 1.02% | -1.2% | |
| MCRB | SERES THERAPEUTICS INC | $6,640,000 | -24.3% | 250,000 | 0.0% | 1.00% | -4.8% | |
| AGEN | AGENUS INC | $6,485,000 | -8.4% | 1,559,000 | 0.0% | 0.98% | +15.3% | |
| PFNX | PFENEX INC | $6,143,000 | -20.6% | 624,900 | 0.0% | 0.92% | -0.1% | |
| FWP | FORWARD PHARMA A/Ssponsored adr | $5,696,000 | -10.5% | 335,068 | 0.0% | 0.86% | +12.6% | |
| WVE | WAVE LIFE SCIENCES LTD | $5,442,000 | -13.0% | 392,079 | 0.0% | 0.82% | +9.6% | |
| XLRN | ACCELERON PHARMA INC | $5,278,000 | -45.9% | 200,000 | 0.0% | 0.80% | -31.9% | |
| CTMX | CYTOMX THERAPEUTICS INC | $4,786,000 | -38.2% | 371,023 | 0.0% | 0.72% | -22.1% | |
| REPH | RECRO PHARMA INC | $4,657,000 | -33.7% | 780,000 | 0.0% | 0.70% | -16.4% | |
| ZYNE | Buy | ZYNERBA PHARMACEUTICALS INC | $4,489,000 | +25.0% | 475,035 | +33.2% | 0.68% | +57.2% |
| ACHN | ACHILLION PHARMACEUTICALS IN | $3,860,000 | -28.5% | 500,000 | 0.0% | 0.58% | -9.9% | |
| DERM | DERMIRA INC | $3,516,000 | -40.2% | 170,000 | 0.0% | 0.53% | -24.7% | |
| AGRX | Buy | AGILE THERAPEUTICS INC | $3,459,000 | +94.7% | 557,053 | +206.0% | 0.52% | +144.6% |
| CYAD | CELYAD SAadr | $3,312,000 | -19.1% | 75,000 | 0.0% | 0.50% | +1.8% | |
| INTEC PHARMA LTD JERUSALEM | $3,296,000 | -23.1% | 800,000 | 0.0% | 0.50% | -3.1% | ||
| EPZM | EPIZYME INC | $3,227,000 | -24.3% | 266,250 | 0.0% | 0.49% | -4.7% | |
| APTOSE BIOSCIENCES INC | $3,179,000 | +16.1% | 1,081,867 | 0.0% | 0.48% | +46.5% | ||
| KITE | KITE PHARMA INC | $3,159,000 | -25.5% | 68,800 | 0.0% | 0.48% | -6.1% | |
| BCRX | BIOCRYST PHARMACEUTICALS | $3,056,000 | -72.6% | 1,080,000 | 0.0% | 0.46% | -65.5% | |
| ATRA | ATARA BIOTHERAPEUTICS INC | $2,855,000 | -27.9% | 150,000 | 0.0% | 0.43% | -9.3% | |
| SNDX | New | SYNDAX PHARMACEUTICALS INC. | $2,856,000 | – | 214,419 | +100.0% | 0.43% | – |
| CFRX | Buy | CONTRAFECT CORP | $2,837,000 | +154.9% | 834,406 | +256.0% | 0.43% | +221.1% |
| BLCM | BELLICUM PHARMACEUTICALS INC | $2,805,000 | -53.9% | 300,000 | 0.0% | 0.42% | -41.9% | |
| LBIO | LION BIOTECHNOLOGIES INC | $2,539,000 | -34.2% | 499,815 | 0.0% | 0.38% | -17.3% | |
| IMDZ | IMMUNE DESIGN CORP | $2,457,000 | -35.3% | 189,000 | 0.0% | 0.37% | -18.5% | |
| EPRSQ | EPIRUS BIOPHARMACEUTICALS IN | $2,412,000 | -12.9% | 896,600 | 0.0% | 0.36% | +9.7% | |
| OVAS | OVASCIENCE INC | $2,393,000 | -2.9% | 252,180 | 0.0% | 0.36% | +22.0% | |
| CRIS | CURIS INC | $1,871,000 | -44.7% | 1,162,400 | 0.0% | 0.28% | -30.4% | |
| RGNX | REGENXBIO INC | $1,693,000 | -34.9% | 156,741 | 0.0% | 0.26% | -18.0% | |
| GLYC | GLYCOMIMETICS INC | $1,690,000 | +4.2% | 283,555 | 0.0% | 0.26% | +31.4% | |
| BITI | BIOTIE THERAPIES OYJsponsored adr | $1,320,000 | +83.8% | 50,000 | 0.0% | 0.20% | +131.4% | |
| AQXP | AQUINOX PHARMACEUTICALS INC | $1,323,000 | -29.3% | 150,000 | 0.0% | 0.20% | -11.2% | |
| FOLD | AMICUS THERAPEUTICS INC | $1,268,000 | -12.9% | 150,000 | 0.0% | 0.19% | +9.8% | |
| TETRALOGIC PHARMACEUTICALS Cnote 8.000% 6/1 | $1,150,000 | -44.7% | 5,000,000 | 0.0% | 0.17% | -30.5% | ||
| ASND | ASCENDIS PHARMA A Ssponsored adr | $1,141,000 | +1.2% | 61,500 | 0.0% | 0.17% | +27.4% | |
| AVEO | AVEO PHARMACEUTICALS INC | $1,001,000 | -27.0% | 1,087,715 | 0.0% | 0.15% | -7.9% | |
| GNVC | GENVEC INC | $948,000 | -56.2% | 1,176,235 | 0.0% | 0.14% | -44.8% | |
| PVCT | PROVECTUS BIOPHARMACEUTICALS | $836,000 | -2.6% | 2,200,000 | 0.0% | 0.13% | +22.3% | |
| VCYT | VERACYTE INC | $745,000 | -25.1% | 137,990 | 0.0% | 0.11% | -5.9% | |
| NSTG | NANOSTRING TECHNOLOGIES INC | $609,000 | +3.6% | 40,000 | 0.0% | 0.09% | +31.4% | |
| HTGM | HTG MOLECULAR DIAGNOSTICS IN | $577,000 | -34.1% | 201,000 | 0.0% | 0.09% | -17.1% | |
| NEOS | NEOS THERAPEUTICS INC | $540,000 | -24.6% | 50,000 | 0.0% | 0.08% | -5.8% | |
| THLD | THRESHOLD PHARMACEUTICALS INC | $460,000 | -4.2% | 1,000,000 | 0.0% | 0.07% | +21.1% | |
| PVCTW | PROVECTUS BIOPHARMACEUTICALS*w exp 06/19/202 | $440,000 | -20.0% | 2,200,000 | 0.0% | 0.07% | 0.0% | |
| DNAI | PRONAI THERAPEUTICS INC | $358,000 | -55.2% | 53,153 | 0.0% | 0.05% | -43.8% | |
| AGTC | APPLIED GENETIC TECHNOL CORP | $239,000 | -31.5% | 17,110 | 0.0% | 0.04% | -14.3% | |
| RGLS | REGULUS THERAPEUTICS INC | $212,000 | -20.6% | 30,656 | 0.0% | 0.03% | 0.0% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $203,000 | -32.8% | 25,000 | 0.0% | 0.03% | -13.9% | |
| CLRB | New | CELLECTAR BIOSCIENCES INC | $180,000 | – | 52,999 | +100.0% | 0.03% | – |
| CLRBW | Sell | CELLECTAR BIOSCIENCES INC*w exp 08/19/201 | $38,000 | -87.2% | 52,999 | -90.0% | 0.01% | -82.9% |
| CLRB | Exit | CELLECTAR BIOSCIENCES INC | $0 | – | -530,000 | -100.0% | -0.05% | – |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -100,000 | -100.0% | -0.32% | – |
| DYAX | Exit | DYAX CORP | $0 | – | -1,400,000 | -100.0% | -6.30% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.